Recent study findings support the current evidence that age-related macular degeneration (AMD) develops when atypical inflammation is present in the eye.
The study was conducted by the Association for Research in Vision and Ophthalmology and involved the review of data between the years of 2010 - 2015 from a large United States commercial insurance database.
Researchers were comparing the risk of AMD in rheumatoid arthritis (RA) patients on TNF-a inhibitors to RA patients on methotrexate. What the researchers discovered was that the sample of the TNF-a inhibitor RA patients did not have an increased risk of developing AMD, But there was an increased risk for the RA patients who had uveitis or scleritis. These findings point to an abnormal immune response being a part of age-related macular degeneration.
Age-related macular degeneration is partially due to inflammation in the macula and is the leading cause of vision loss in the elderly within the United States. VisiVite offers multiple AREDS 2 formulas for those with a diagnosis of age-related macular degeneration.